Multiple Sclerosis Clinical Trial
Official title:
A Randomized Allocation of Palliative Care Consultation in the Emergency Department Compared to Usual Practice
Verified date | August 2016 |
Source | Wayne State University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
A prospective randomized controlled trial studying the ordering of palliative care consultations in the emergency department (Ig) versus later palliative care consultations in the hospital--ICU or hospital ward(Cg). Patients will be randomly allocated to Ig or Cg with a 1:1 ratio.
Status | Active, not recruiting |
Enrollment | 120 |
Est. completion date | |
Est. primary completion date | January 2017 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 65 Years and older |
Eligibility |
Inclusion Criteria: - Greater than or equal to 65 years old - Treated in a resuscitation room for unstable vital signs or respiratory compromise - One or more of the following: - Advanced or metastatic solid organ cancer - End stage organ failure of the heart, lung/COPD, kidney on dialysis, hepatic encephalopathy - Suspected sepsis - Advanced dementia, end-state multiple sclerosis or Parkinson's disease - Status post cardiac arrest with coma (Glascow coma score <7) - Patient is from a skilled nursing facility Exclusion Criteria: - Lack decision capacity and have no relative available during ED stay to consent to the study (legally authorized representative—LAR) - Enrolled in hospice care prior to randomization - A copy of a completed advance directive which names a designated proxy provided physically to the medical team prior to randomization - Wearing a DNR bracelet - Have been previously enrolled in this study |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
United States | Detroit Medical Center Detroit Receiving Hospital | Detroit | Michigan |
United States | Detroit Medical Center Sinai Grace Hospital | Detroit | Michigan |
Lead Sponsor | Collaborator |
---|---|
Wayne State University | Blue Cross Blue Shield of Michigan Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The difference in the percentage of patients with a completed advance directive (AD) in Ig vs.Cg | 1 year | No | |
Secondary | The proportion of billed CMS ACP-CPT codes in Ig vs. Cg | The proportion of patients who received an ACP CMS billing codes (which took effect in January 2016), in Ig vs. Cg will be evaluated using one or both of the new CPT codes for Advance care planning (ACP) services…including the explanation and discussion of advance directives such as standard forms (with the completion of such forms, when performed) by the physician or other qualified health profession; first 30 (15-45)minutes, face to face with the patients, family member(s) and/or surrogate Code 99497; and each additional 30 (46-75 minutes)—Code 99498 (Federal Register, 2015). | 30 days from enrolled patients' hospital discharge | No |
Secondary | Matches of care received to patient-specific preferences in Ig vs. Cg | The investigators will align treatment preferences with medical orders, replicated as reported in the study by Mack et al. Proportions of patients coded as having a match will be compared across the treatment and control groups. For everyone who gets ACP during the study, patients or their surrogates will be asked by a member of the care team—either palliative care if they are consulted, or the hospital based care team if they are not: "If you could choose, would you prefer (a) treatment that focuses on attempting to extend your time as much as possible, even if doing so means more pain and discomfort, or (b) a plan of care that focuses on relieving pain and discomfort and improving quality of life, even though that may mean not living as long. | 1 year | No |
Secondary | Patient/family satisfaction with care in Ig vs. Cg | This outcome will be measured on a continuous scale. The net-promoter score will be measured at baseline (at randomization) and at hospital discharge for a change in value. It is measured on a scale of 1-10. Whoever signs the consent (patient of LAR) will be asked the net promoter score, and that will be reassessed by them at discharge, unless the patient has died—and the variable will then be recorded as missing. The PSQ will be administered by research assistants at the time of the patient's discharge. If the patient is incapacitated, then it will be asked of the patient's closest family caregiver. So PSQ is only at discharge of patient or available, most involved, family caregiver. | Baseline | No |
Secondary | Amount of hospice referrals in Ig vs. Cg | 1 year | No | |
Secondary | Hospital total direct costs for the index visit in Ig vs. Cg | 1 year | No | |
Secondary | Hospital and ICU length of stay in Ig vs. Cg | 1 year | No | |
Secondary | Average days in hospice in Ig vs. Cg | 1 year | No | |
Secondary | Hospital margin contribution for the index visit in Ig vs. Cg | 1 year | No | |
Secondary | Time to consultation in Ig vs. Cg groups | 1 year | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |